List of Excipients in Branded Drug FLAGYL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc	FLAGYL	metronidazole	0025-1831	ALUMINUM OXIDE
Pfizer Laboratories Div Pfizer Inc	FLAGYL	metronidazole	0025-1831	FD&C BLUE NO. 2
Pfizer Laboratories Div Pfizer Inc	FLAGYL	metronidazole	0025-1831	HYPROMELLOSE
Pfizer Laboratories Div Pfizer Inc	FLAGYL	metronidazole	0025-1831	POLYETHYLENE GLYCOL
Pfizer Laboratories Div Pfizer Inc	FLAGYL	metronidazole	0025-1831	POWDERED CELLULOSE

Flagyl Excipient Strategy and Commercial Opportunities for Metronidazole

Last updated: July 31, 2026

Flagyl is the original branded formulation of metronidazole, an antibacterial and antiprotozoal drug used in gastrointestinal, anaerobic, gynecologic, dental, and dermatologic indications. Its core composition is no longer protected by meaningful U.S. market exclusivity. Commercial opportunity therefore lies in excipient-enabled differentiation: taste masking, pediatric delivery, modified local exposure, preservative-free products, improved vaginal and topical tolerability, and supply-chain advantages.

The strongest opportunities are in metronidazole products that address administration problems rather than attempting to compete with low-cost immediate-release tablets on price alone.

What is Flagyl and which dosage forms contain metronidazole?

Flagyl contains metronidazole, a nitroimidazole antimicrobial. The product has been marketed in multiple dosage forms, including oral tablets, intravenous injection, vaginal gel, and topical formulations. Generic metronidazole products are widely available in the United States and internationally.

Product category	Route	Primary commercial use	Excipient strategy
Flagyl tablets	Oral	Anaerobic bacterial and protozoal infections	Taste, disintegration, coating, swallowability
Metronidazole capsules and tablets	Oral	Systemic treatment	Low-cost manufacturing and bioequivalence
Metronidazole oral suspension	Oral	Pediatric and dysphagic patients	Taste masking, suspension stability, preservative system
Metronidazole injection	Intravenous	Hospital treatment	Osmolality, pH, container compatibility, preservative-free delivery
Metronidazole vaginal gel	Vaginal	Bacterial vaginosis and related infections	Mucoadhesion, vaginal retention, low irritation
Metronidazole topical gel or cream	Topical	Rosacea and other dermatologic conditions	Skin feel, permeation control, preservative and packaging compatibility

FDA-approved metronidazole products vary in inactive ingredients. The exact excipient composition depends on the dosage form, strength, manufacturer, and market. Product-specific labels and DailyMed entries should control formulation comparisons.[1]

What excipients are used in Flagyl tablets?

Flagyl immediate-release tablets use conventional pharmaceutical excipients for tablet formation, mechanical strength, disintegration, coating, and color. The commercial formulation is built around a low-cost, high-volume oral solid-dose platform rather than a novel delivery system.

Typical excipient functions in metronidazole tablets include:

• Fillers and binders to provide tablet mass and compression strength.
• Disintegrants to promote breakup after ingestion.
• Glidants and lubricants to improve powder flow and ejection.
• Film-coating polymers to improve appearance, handling, and swallowability.
• Pigments or colorants for product identification.
• Moisture-control components where needed for stability.

The specific Flagyl label identifies inactive ingredients for each marketed dosage form. Generic manufacturers are not required to copy the originator’s excipients, but their formulations must meet applicable quality, bioequivalence, safety, and labeling requirements.[1,2]

Why the tablet excipient estate has limited defensive value

The basic excipient architecture of an immediate-release metronidazole tablet is conventional. Excipients such as starches, cellulose derivatives, povidone, crospovidone, silicon dioxide, stearates, and coating polymers are broadly used across the pharmaceutical industry.

A competitor would generally obtain limited protection from using a standard tablet excipient combination unless it could demonstrate:

1. A non-obvious quantitative composition.
2. A measurable improvement in dissolution, stability, manufacturability, or tolerability.
3. A narrow particle-size or process limitation.
4. A formulation result that would support patent enablement and inventive-step requirements.
5. Commercial value sufficient to offset development and regulatory costs.

What excipient opportunities exist for metronidazole oral products?

The largest oral opportunity is not a new tablet. It is an acceptable liquid or orally disintegrating product that solves metronidazole’s well-known administration and taste problems.

Taste-masked pediatric suspension

Metronidazole has a strong, unpleasant taste that can reduce adherence, particularly in children. A ready-to-use or reconstituted suspension could create value through:

• Ion-exchange resins.
• Polymer coating of metronidazole particles.
• Lipid or lipid-polymer microparticles.
• Cyclodextrin complexation.
• pH-controlled flavor suppression.
• Sweetener and flavor systems designed for pediatric use.
• Suspending agents that limit sedimentation and dose variability.

A taste-masked suspension must preserve rapid drug release after swallowing. Excessive coating or complexation can delay dissolution and create bioequivalence problems.

Commercially, a pediatric product could compete with extemporaneous pharmacy compounding. The opportunity is strongest where hospitals and pharmacies currently rely on short-dated compounded suspensions.

Orally disintegrating tablets

An orally disintegrating tablet could target patients who cannot swallow conventional tablets. Commercial differentiation would depend on:

• Low tablet weight.
• Rapid disintegration without excessive friability.
• Taste masking that survives rapid oral dispersion.
• Low residual bitterness.
• Packaging that protects against moisture.
• Compatibility with metronidazole’s dose requirements.

The product would face a significant taste challenge because rapid oral dispersion increases exposure to taste receptors. A conventional film-coated tablet is easier to manufacture and may remain the lower-cost product.

Sprinkle or multiparticulate delivery

A sprinkle formulation could improve administration for pediatric or dysphagic patients. Drug-containing pellets or granules could be coated with a taste-masking layer and administered with soft food.

The formulation must control:

• Dose uniformity.
• Coating integrity during storage and handling.
• Release after ingestion with food.
• Risk of chewing and premature taste exposure.
• Compatibility with feeding tubes, if claimed.

Multiparticulate products may support a stronger formulation patent position than ordinary tablets because the patent can focus on particle structure, coating thickness, polymer selection, and release performance.

What excipients can differentiate metronidazole vaginal products?

Metronidazole vaginal gel is a more attractive excipient platform than the immediate-release tablet because local retention, tolerability, and administration convenience affect product performance.

Mucoadhesive vaginal gels

Mucoadhesive polymers can extend residence time and reduce leakage. Potential excipient classes include:

• Carbomers.
• Polycarbophil.
• Cellulose derivatives.
• Poloxamers.
• Thiolated polymers.
• Hydrogel-forming polymer blends.

A successful formulation must balance retention against patient acceptability. Excessive viscosity can impair application, increase leakage during removal, or create an unfavorable sensory profile.

The commercial case is strongest for a low-volume, once-daily product with improved retention and less mess than conventional gel. A formulation that reduces dosing frequency could support a method-of-use or formulation patent, although the clinical benefit must be demonstrated.

pH and microbiome considerations

Vaginal formulations require careful control of pH, osmolality, preservative exposure, and polymer irritation. An excipient system that maintains a physiologically acceptable environment may improve tolerability, but claims about microbiome preservation require clinical substantiation.

Preservative-free packaging could be commercially relevant for patients with sensitivity to antimicrobial preservatives. Single-dose applicators, unit-dose tubes, or airless systems can reduce contamination risk and simplify administration.

Extended-release vaginal delivery

Metronidazole-loaded gels, films, tablets, rings, and bioadhesive inserts could reduce administration frequency. The main technical barriers are:

• Consistent local release.
• Adequate coverage of vaginal tissue.
• Product retention during movement and intercourse.
• Absence of excessive leakage.
• Patient comfort.
• Scalable manufacturing.

Extended-release delivery creates more protectable intellectual property than a standard gel, particularly where the dosage form includes a defined polymer matrix, release profile, or applicator system.

What excipients are relevant to topical metronidazole products?

Topical metronidazole products for rosacea compete on cosmetic acceptability as much as on drug delivery. Excipient strategy can focus on reducing dryness, tackiness, odor, pilling, and visible residue.

Relevant formulation approaches include:

• Oil-in-water emulsions for improved skin feel.
• Non-greasy gels for facial use.
• Silicone-containing systems for spreadability.
• Humectants to reduce dryness.
• Barrier-supportive emollients.
• Low-irritancy preservative systems.
• Airless packaging to limit oxidation and contamination.
• Microsphere or nanoparticle systems for controlled deposition.

A topical metronidazole product with improved cosmetic properties may gain market share even without superior antimicrobial efficacy. The regulatory burden depends on the product’s formulation, claims, route, and reference-product pathway.

For generic topical products, formulation complexity can create meaningful development barriers because demonstrating bioequivalence may require comparative clinical endpoint studies, in vitro release testing, or other product-specific evidence.[3]

What formulation patents could protect a new metronidazole product?

The strongest patent opportunities are likely to involve delivery architecture rather than the metronidazole molecule itself.

Potential patentable subject matter

Patent category	Example claim focus	Commercial value
Taste masking	Coated particles, resin complexes, polymer barriers	Pediatric and dysphagia markets
Oral suspension	Particle-size distribution, suspending system, shelf life	Replacement for compounded products
Vaginal gel	Mucoadhesive polymer ratios and retention	Lower leakage and less frequent dosing
Vaginal insert	Matrix composition and release profile	Extended local therapy
Topical gel	Deposition, skin feel, preservative system	Dermatology differentiation
Packaging	Unit-dose applicator or airless container	Convenience and contamination control
Manufacturing process	Continuous coating, granulation, drying, or sterilization	Cost and reproducibility
Combination product	Metronidazole with another antimicrobial or active	Broader treatment positioning

A formulation patent should connect the excipient selection to a measurable result. Broad claims covering “metronidazole and a pharmaceutically acceptable excipient” are vulnerable to prior-art attacks and may be difficult to enforce.

When does Flagyl lose exclusivity?

Flagyl’s core active-ingredient exclusivity expired long ago. Metronidazole is a mature generic active ingredient, and FDA-approved generic oral and injectable products have been available for decades.

Exclusivity type	Flagyl status
New chemical entity exclusivity	Expired
Core composition-of-matter patent	Expired
Original oral tablet exclusivity	Expired
Generic oral entry	Established
Generic injectable entry	Established
Current product-specific exclusivity	No material barrier to ordinary generic competition
Formulation-specific exclusivity	Depends on any separate product or later approval

The precise Orange Book status must be assessed by dosage form and active FDA listing. The Orange Book is the controlling source for listed patents and approved generic applications.[2]

What is the Orange Book status of Flagyl?

Flagyl does not have a commercially meaningful Orange Book position that blocks generic metronidazole tablets or injection. The original brand’s market position is based on historical recognition, hospital familiarity, and distribution rather than current patent exclusivity.

A product-specific Orange Book analysis should review:

• The relevant Flagyl NDA.
• Active dosage forms and strengths.
• Listed patents, if any.
• Patent delisting or expiration records.
• Approved ANDAs.
• Any current exclusivity codes.
• Whether the proposed product is an RLD or reference standard for the relevant dosage form.

A new formulation would not automatically receive Orange Book listing. FDA listing depends on the approved NDA or supplement and the patent’s relationship to the approved drug. A formulation patent may be listed when it claims the drug product or an approved method of use, subject to FDA requirements.[2,4]

Which companies are challenging Flagyl exclusivity?

Generic competition has already removed the principal barrier to metronidazole entry. The relevant competitive field includes large generic manufacturers, hospital suppliers, specialty dermatology companies, compounding pharmacies, and contract development and manufacturing organizations.

Potential competitors include companies that market:

• Generic metronidazole tablets and capsules.
• Injectable metronidazole.
• Vaginal gel.
• Topical gel and cream.
• Compounded oral suspensions.
• Combination products for bacterial vaginosis or dermatologic use.

A modern Paragraph IV campaign against the original Flagyl product would have limited strategic value because the core active and conventional dosage forms are already generic. Paragraph IV risk becomes relevant only for a newer, separately patented metronidazole formulation or combination product.

What generic entry risks exist for a new metronidazole formulation?

Generic entry risk is high for conventional oral tablets and low-complexity topical products. It is more manageable for products with difficult delivery systems.

Product concept	Generic entry risk	Main reason
Immediate-release tablet	Very high	Mature technology and abundant prior art
Standard oral capsule	Very high	Simple dosage form
Conventional oral suspension	High	Established excipient technologies
Taste-masked multiparticulate	Moderate	Coating and bioequivalence complexity
Vaginal mucoadhesive gel	Moderate	Product-performance and local-delivery requirements
Extended-release vaginal insert	Moderate to low	More complex formulation and clinical evidence
Advanced topical delivery system	Moderate	Comparative performance may be difficult
Sterile preservative-free injection	Moderate	Manufacturing and container-closure barriers

Patent protection is only one part of the barrier. Scale-up, stability, clinical endpoint requirements, device compatibility, and manufacturing validation may delay competitors even when the patent estate is narrow.

How strong is the patent estate for Flagyl?

The patent estate for the original Flagyl product is weak as a current exclusivity asset. The metronidazole molecule and conventional formulations are mature. Any commercial protection would need to come from a later formulation, delivery device, manufacturing process, or combination product.

A strong metronidazole patent program would generally include:

1. Composition claims covering the defined excipient system.
2. Process claims covering manufacture of the dosage form.
3. Use claims covering a differentiated dosing regimen or patient population.
4. Device claims covering applicators or delivery systems.
5. Backup claims covering alternative polymers, particle sizes, and release profiles.
6. Data showing improved stability, tolerability, adherence, or pharmacokinetics.

The strongest claims would be supported by comparative evidence against generic metronidazole and the relevant Flagyl dosage form.

What FDA regulatory pathway applies to new Flagyl alternatives?

A conventional generic metronidazole product generally follows the ANDA pathway and must demonstrate pharmaceutical equivalence and bioequivalence to the applicable reference product.[3]

A materially differentiated product may require an NDA or 505(b)(2) application. This pathway is relevant where the sponsor relies partly on existing findings for metronidazole but introduces a new dosage form, route, formulation, dosing regimen, or delivery technology.

Development type	Likely U.S. pathway
Same-strength immediate-release tablet	ANDA
Standard generic vaginal gel	ANDA, subject to product-specific requirements
New taste-masked suspension	ANDA or 505(b)(2), depending on reference and formulation
Extended-release vaginal insert	505(b)(2) or NDA
New topical delivery system	ANDA, 505(b)(2), or NDA depending on product differences
New combination product	NDA or applicable combination-product pathway

Novel excipients may require additional toxicology and regulatory support. Using excipients with established pharmaceutical use and FDA Inactive Ingredient Database precedent generally reduces regulatory risk, although route-specific exposure remains important.[5]

Are biosimilar risks relevant to Flagyl?

No. Flagyl is a small-molecule metronidazole product, not a biologic. Biosimilar competition does not apply. The relevant competitors are generic drugs, authorized generics, branded reformulations, specialty formulations, and compounded products.

What licensing deals could create commercial value?

Licensing opportunities are more likely to involve delivery technology than the Flagyl brand itself. Potential deal structures include:

• In-licensing of taste-masking technology for pediatric metronidazole.
• Regional licensing of vaginal delivery systems.
• Co-development of an extended-release insert.
• Supply agreements for coated metronidazole microparticles.
• Licensing of topical dermatology platforms.
• Contract manufacturing partnerships for sterile injection or unit-dose vaginal products.
• Acquisition of a formulation patent family with 505(b)(2) potential.

A license should be valued against the size of the target market, clinical evidence required, formulation reproducibility, freedom-to-operate risk, and expected generic timing. A standard metronidazole tablet license has limited value because price competition is established.

What is the commercial opportunity for Flagyl excipient innovation?

The most credible opportunities are concentrated in underserved administration segments.

Priority opportunities

1. Pediatric ready-to-use suspension with strong taste masking.
2. Sprinkle granules for patients unable to swallow tablets.
3. Once-daily mucoadhesive vaginal gel.
4. Low-leakage vaginal film or insert.
5. Preservative-free unit-dose vaginal product.
6. Cosmetic-grade topical metronidazole formulation.
7. Stable, ready-to-use sterile injection presentation.
8. Metronidazole combination product with a differentiated local-delivery profile.

Revenue exposure from the legacy Flagyl brand is difficult to separate from broader metronidazole sales because generic products dominate the market and public companies generally report metronidazole within larger product categories. The economic case for a new product should therefore be based on a defined premium segment, not on recovery of the historical Flagyl tablet franchise.

What manufacturing and intellectual-property barriers matter most?

Manufacturing barriers can provide practical protection where composition claims are narrow.

The most relevant barriers include:

• Uniform coating of high-dose metronidazole particles.
• Controlling bitterness without slowing dissolution.
• Maintaining suspension uniformity throughout shelf life.
• Sterile manufacture and container compatibility for injection.
• Reproducible vaginal polymer hydration and release.
• Scale-up of low-viscosity topical systems.
• Control of residual solvents or degradation products.
• Packaging that protects moisture-sensitive dosage forms.
• Consistent dose delivery through applicators or feeding tubes.

A formulation program should pursue a layered IP strategy. Composition claims alone may not withstand generic design-around. Process, packaging, device, release-profile, and use claims can increase the practical cost of substitution.

Key Takeaways

• Flagyl’s original metronidazole exclusivity has expired, and conventional tablets face intense generic competition.
• Excipient innovation is commercially relevant only when it solves a clear administration or tolerability problem.
• Taste-masked pediatric suspensions and multiparticulates offer the strongest oral opportunities.
• Mucoadhesive, extended-release, preservative-free, or low-leakage vaginal products have greater differentiation potential than standard gel.
• Topical products can compete through cosmetic acceptability, skin feel, and packaging.
• A new formulation may require an ANDA, 505(b)(2), or NDA depending on its differences from the reference product.
• Flagyl has no biosimilar risk because metronidazole is a small molecule.
• Strong protection would require formulation, process, device, and method-of-use claims supported by comparative performance data.
• The commercial case should target premium administration segments rather than the mature generic tablet market.

FAQs About Flagyl Excipient Strategy

Can a new excipient make metronidazole eligible for a new patent?

Yes. A new excipient may support patent protection when it is part of a non-obvious composition that produces a demonstrated technical benefit, such as improved taste masking, stability, retention, or release control.

Is metronidazole oral suspension a commercially attractive product?

Yes, particularly where pharmacies and hospitals rely on compounded suspensions. The principal development challenge is masking metronidazole’s strong bitterness while maintaining dose uniformity and rapid release.

Can a vaginal metronidazole gel receive Orange Book-listed patents?

Potentially. A patent may be eligible for listing if it claims the approved drug product or an approved method of use and meets FDA listing requirements. A general excipient patent unrelated to the approved product would not automatically qualify.

Would an orally disintegrating Flagyl product avoid generic competition?

No. It could obtain formulation protection, but generic competition would remain likely after patent expiry. The product would need meaningful taste masking, convenience, or adherence benefits to support a premium.

What is the best commercial formulation strategy for metronidazole?

A pediatric taste-masked suspension or multiparticulate product is the most direct opportunity. A once-daily mucoadhesive vaginal system offers a stronger differentiated platform but requires more development and clinical evidence.

References

1. National Library of Medicine. (n.d.). DailyMed: Flagyl and metronidazole product labeling. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2023). Generic drug facts and bioequivalence requirements. FDA.

4. U.S. Food and Drug Administration. (2015). Listing of patent information in approved drug products and patent certifications. FDA.

5. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. FDA.